NCT05982834 2023-08-09
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
Fudan University
Phase 1/2 Unknown
Clinical Trials
4 trialsNCT05311189 2022-04-05
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05270889 2022-03-08
Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial
Yonsei University
Phase 2 Unknown
NCT05070598 2021-10-07
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
Shengjing Hospital
Phase 2 Unknown